I think most RAC investors are aware of this information. We know of the changes going on in the AML market which is why we are moving to a low intensity use of bisantrene in AML. The upcoming AML trial will use bisantrene as a low intensity treatment that will be able to be used in ‘unfit’ patients. Of course this approach requires that we have a form of bisantrene that can be used in an outpatient environment and this is exactly what RC220 offers.
CPACS: Research, Results, Market Comparisons, and Valuations, page-82
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.015(0.93%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $60.29K | 37.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 800 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 931 | 2 |
View Market Depth
| Last trade - 13.02pm 13/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |